论文部分内容阅读
目的 :比较倍他乐克和硫氮 卓艹 酮治疗左室舒张性心力衰竭 (DHF)的临床疗效。方法 :63例DHF患者随机分为倍他乐克组 3 1例及硫氮 卓艹 酮组 3 2例 ,由小剂量开始 ,在无不良反应且症状体征逐渐改善的情况下 ,逐渐增加到最大耐受量 ,疗程半年 ,观察二组心功能及心功能参数改善情况。结果 :二组心功能及心功能参数均较治疗前有明显改善 ,两组相比无明显差异。结论 :对于左室舒张性心力衰竭患者倍他乐克和硫氮 卓艹 酮都有显著的疗效 ,均可作为DHF的首选药物。
Objective: To compare the clinical efficacy of metoprolol and thiazolidinone in the treatment of left ventricular diastolic heart failure (DHF). Methods: Sixty-three patients with DHF were randomly divided into 31 patients in the Betaloc group and 32 patients in the DMZ group. The dose of DHF was gradually increased from the lowest dose to the largest without any adverse reaction with gradual improvement of symptoms and signs Tolerance, treatment six months, two groups of heart function and cardiac function parameters to improve the situation. Results: The cardiac function and cardiac function parameters of the two groups were significantly improved compared with those before treatment, there was no significant difference between the two groups. CONCLUSION: Betaloc and DSA have significant efficacy in patients with left ventricular diastolic heart failure, and both can be used as the drug of choice for DHF.